Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria J Muir

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 26, 2011
Erlotinib: as maintenance monotherapy in non-small-cell lung cancerVictoria J Muir, Sohita Dhillon
CNS Drugs|February 18, 2011
Cladribine tablets: in relapsing-remitting multiple sclerosisVictoria J Muir, Greg L Plosker
Drugs|December 15, 2010
Olmesartan medoxomil: in children and adolescents with hypertensionVictoria J Muir, Gillian M Keating
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 5, 2011
Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumors: profile reportLesley J Scott, Victoria J Muir
Drugs|August 25, 2010
Guanfacine extended-release: in attention deficit hyperactivity disorderVictoria J Muir, Caroline M Perry
Drugs|June 15, 2011
Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumoursLesley J Scott, Victoria J Muir
Paediatric Drugs|April 14, 2012
Olmesartan medoxomil in children and adolescents with hypertension†: profile reportVictoria J Muir, Gillian M Keating
CNS Drugs|March 12, 2020
Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple SclerosisVictoria J Muir, Greg L Plosker
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 4, 2010
Denosumab: in cancer treatment-induced bone lossVictoria J Muir, Lesley J Scott
Drugs|June 15, 2011
Botulinum toxin A (Dysport®): in dystonias and focal spasticitySusan J Keam, Victoria J Muir, Emma D Deeks
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 26, 2011
Erlotinib: as maintenance monotherapy in non-small-cell lung cancerVictoria J Muir, Sohita Dhillon
CNS Drugs|February 18, 2011
Cladribine tablets: in relapsing-remitting multiple sclerosisVictoria J Muir, Greg L Plosker
Drugs|December 15, 2010
Olmesartan medoxomil: in children and adolescents with hypertensionVictoria J Muir, Gillian M Keating
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 5, 2011
Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumors: profile reportLesley J Scott, Victoria J Muir
Drugs|August 25, 2010
Guanfacine extended-release: in attention deficit hyperactivity disorderVictoria J Muir, Caroline M Perry
Drugs|June 15, 2011
Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumoursLesley J Scott, Victoria J Muir
Paediatric Drugs|April 14, 2012
Olmesartan medoxomil in children and adolescents with hypertension†: profile reportVictoria J Muir, Gillian M Keating
CNS Drugs|March 12, 2020
Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple SclerosisVictoria J Muir, Greg L Plosker
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 4, 2010
Denosumab: in cancer treatment-induced bone lossVictoria J Muir, Lesley J Scott
Drugs|June 15, 2011
Botulinum toxin A (Dysport®): in dystonias and focal spasticitySusan J Keam, Victoria J Muir, Emma D Deeks
Pageof 2